NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00448227
- Locations
- 🇺🇸
Children's Memorial Hospital Chicago, Chicago, Illinois, United States
🇺🇸Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸Archana Chatterjee, Omaha, Nebraska, United States
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00447694
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
- Conditions
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00446563
- Locations
- 🇩🇪
25 centers in Germany, Ludwigshafen, Germany
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 403
- Registration Number
- NCT00446524
- Locations
- 🇯🇵
Novartis Investigative Site, Fukuoka, Japan
Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function
- Conditions
- Interventions
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2011-04-05
- Lead Sponsor
- Novartis
- Target Recruit Count
- 265
- Registration Number
- NCT00444106
- Locations
- 🇨🇴
Novartis Investigational Site, Tumaco, Colombia
Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)
- Conditions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00443482
- Locations
- 🇩🇪
Novartis Investigative Site, Wiesbaden, Germany
Efficacy and Safety of Diclofenac Sodium (0.1%) Gel in Patients With UV Induced Painful Sunburn
- Conditions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2007-02-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00441051
- Locations
- 🇫🇷
CPCAD, Nice, France
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00441064
- Locations
- 🇺🇸
Novartis US, Madison, Wisconsin, United States
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 412
- Registration Number
- NCT00439244
- Locations
- 🇩🇪
Novartis Investigative site, Wuerzburg, Germany
🇪🇸Novartis Investigative Site, Valencia, Spain
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 321
- Registration Number
- NCT00436553
- Locations
- 🇺🇸
Novartis Investigative SIte, Royal Oak, Michigan, United States
🇨🇦Ivey Eye Institute, Dr. Thomas Sheidow, London, Ontario, Canada
🇺🇸West Coast Retina Medical Group Inc. - 185 Berry St. Suite 130, San Francisco, California, United States